Patents Examined by Nizal S. Chandrakumar
  • Histone demethylase inhibitors
    Patent number: 11731954
    Abstract: The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds. The subject compounds and compositions are useful for inhibition of at least one histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer or neoplastic disease, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, retinoblastoma, or multiple endocrine neoplasia type 1.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: August 22, 2023
    Inventors: Young K. Chen, Michael Brennan Wallace
  • Ultra short acting anti-arrhythmic agents
    Patent number: 11731938
    Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: August 22, 2023
    Assignee: Academic Pharmaceuticals Inc
    Inventors: John Somberg, Robert J Chorvat
  • Treatment of congenital adrenal hyperplasia
    Patent number: 11730739
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: August 22, 2023
    Assignee: Neurocrine Biosciences, Inc.
    Inventor: Dimitri E. Grigoriadis
  • Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
    Patent number: 11724986
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 15, 2023
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Macrocyclic compound and uses thereof
    Patent number: 11725015
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: August 15, 2023
    Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Compounds and compositions for treating conditions associated with APJ receptor activity
    Patent number: 11724997
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 15, 2023
    Assignee: Annapurna Bio, Inc.
    Inventors: Haifeng Tang, Sarah Boyce, Michael Hanson, Zhe Nie
  • N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
    Patent number: 11718613
    Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 8, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jianyong Chen
  • Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
    Patent number: 11718619
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: August 8, 2023
    Assignee: Ardelyx, Inc.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
    Patent number: 11713324
    Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: August 1, 2023
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Graham Beaton, Mi Chen, Timothy Richard Coon, Todd Ewing, Wanlong Jiang, Willy Moree, Martin Rowbottom, Warren Wade, Liren Zhao, Richard Lowe, Nicole Smith, Neil Ashweek, Yun-Fei Zhu
  • Short conjugated oligoelectrolytes and uses thereof
    Patent number: 11713318
    Abstract: Compositions and methods of making and using thereof are provided with a specific antimicrobial activity and efficacy toward Gram-positive and Gram-negative bacteria and low levels of toxicity toward mammalian cells. The compositions include water-soluble molecules characterized by a hydrophobic interior fragment and side groups containing cationic groups. A class of these molecules is provided with variations in the length of the internal conjugated segment and in other molecular features, which impact the efficacy and toxicity. The substituents on the cationic functional group, the structural variations on the solubilizing group, and the length of the conjugated segment are important features affecting the antimicrobial property and the non-toxicity to mammalian cells of the composition.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: August 1, 2023
    Assignee: The Regents Of The University Of California
    Inventors: Guillermo Bazan, Zichao Zhang, Alex Moreland, Michael J. Mahan, Douglas M. Heithoff, Jakkarin Limwongyut, Chenyao Nie
  • Inhibitors of androgen receptor signaling
    Patent number: 11708381
    Abstract: The present disclosure relates to androgen receptor signaling inhibitors and the synthesis of the same. Further, the present disclosure teaches the utilization of the androgen receptor signaling inhibitors in a treatment for proliferative diseases, including cancer, particularly prostate cancer, and especially castration-resistant prostate cancer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 25, 2023
    Assignee: XAVIER UNIVERSITY OF LOUISIANA
    Inventors: Guangdi Wang, Jiawang Liu, Shilong Zheng, Shanchun Guo
  • N-formyl vortioxetine and preparation method thereof and solid preparation of vortioxetine
    Patent number: 11707461
    Abstract: Disclosed is N-formyl vortioxetine, and also disclosed is a method for preparing the N-formyl vortioxetine and a stable solid preparation of vortioxetine.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 25, 2023
    Assignee: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD
    Inventors: Jinsheng Lin, Tianpei Huang, Feifei Lan, Xiaoyan Xu, Libin Hu, Dan Li, Wenquan Zhu, Min Li, Zhiyun Wang
  • Antiviral composition for SARS-CoV-2 containing cannabinoids as active ingredient
    Patent number: 11707444
    Abstract: The present invention relates to an antiviral composition and a screening method thereof for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that occurred in Wuhan, China in 2019. An extract from leaves or unfertilized female flowers of Cannabis sativa L. or its fraction, and the cannabinoids (CBDs) molecules isolated from it have high binding strength and stability to SARS-CoV-2 MPpro, thereby inhibiting its action as the main protease, to provide a useful lead molecule that can be used alone or in combination with other drugs to treat SARS-CoV-2.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: July 25, 2023
    Assignees: RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jintae Lee, Jungyeob Ham, Taejung Kim
  • Hydrophobic compounds for optically active devices
    Patent number: 11702396
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: July 18, 2023
    Assignee: Johnson & Johnson Surgical Vision, Inc.
    Inventors: Lars Dobelmann-Mara, Stefan Riedmueller, Martin Schraub
  • Substituted bicyclic compounds
    Patent number: 11701373
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: July 18, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • Use of gTso thal in manufacturing medicament for promotion of MS-275 to cross blood-brain barrier
    Patent number: 11701338
    Abstract: The present invention relates to use of gTso thal in manufacturing a medicament for the promotion of MS-275 to cross the blood-brain barrier (BBB), and belongs to the technical field of pharmaceutical preparation. Administration of the medicament manufactured by the use of the present invention in combination with MS-275 significantly increases MS-275 to cross the BBB into the brain tissue, and prominently promotes the accumulation of MS-275 therein.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: July 18, 2023
    Assignee: Northwest Institute of Plateau Biology, Chinese Academy of Sciences
    Inventors: Xiaohui Zhao, Ting Zhang, Huilan Yue, Jihong Tao, Wenjing Jia, Guoying Zhou, Lixin Wei, Chen Chen
  • Pain-relieving topical compositions
    Patent number: 11696909
    Abstract: Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: July 11, 2023
    Assignee: INNOCAN PHARMA LTD.
    Inventor: Nir Avram
  • Process for synthesis of eliglustat and intermediate compounds thereof
    Patent number: 11697644
    Abstract: A method for synthesis of Eliglustat and intermediate compounds thereof. Specifically, a method for synthesis of Eliglustat and pharmaceutically acceptable salts thereof, and further to intermediate compounds used in the method and a preparation method for the intermediate compounds. Compared with an existing synthesis method, the method for synthesis of Eliglustat of the present invention uses novel synthetic intermediates and synthesis steps, features ease of operation, high yield, good purity of intermediates and target products, etc., and facilitates industrial production.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 11, 2023
    Assignee: ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
    Inventors: Yu Liu, Guanneng Yu, Zhiguo Zheng
  • Prolonged ectoparasite-controlling agent for animal
    Patent number: 11696913
    Abstract: A compound represented by Formula (1) can be used as a prolonged ectoparasite-controlling agent for an animal. A preparation for systemic application for use in prolonged control of an ectoparasite in an animal include the compound. A method for prolonged control of an ectoparasite on an animal includes systemically applying the compound. The compound may be used for preparing a medicament for prolonged control of an ectoparasite on an animal. A horticultural or agricultural insecticide containing the compound, and a method of protecting a crop from a harmful organism is also provided.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: July 11, 2023
    Assignee: MITSUI CHEMICALS AGRO, INC.
    Inventors: Yoji Aoki, Shinichi Banba, Markus Berger, Lars Baerfacker
  • Isoquinoline-steroid conjugates and uses thereof
    Patent number: 11691950
    Abstract: Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: July 4, 2023
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Eric Carlson, Casey Kopczynski, Jill M. Sturdivant, Cynthia Lichorowic